At a glance
ClinicalIndex Comparison Record- ✓Confirmed diagnosis of CLL/SLL per iwCLL 2018 criteria
- ✓Part 1: Prior CLL/SLL treatment (1-3 lines)
- ✓Part 1: Prior covalent BTK inhibitor
- ✓Part 2: No prior CLL/SLL treatment
- ✕Prior BTK degrader or noncovalent BTK inhibitor
- ✕History of Grade ≥3 bleeding due to BTK inhibitor treatment
- ✕Known or suspected Richter's transformation
- ✕Known or suspected CNS involvement by CLL/SLL
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
In Brief
A Phase 2 clinical trial evaluating Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Currently recruiting, targeting 249 participants across 131 sites in 18 countries.
Signals
Detailed Summary
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
Study Details
Timeline
Interventions
Administered Orally.